---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-015525"
form_type: "8-K"
ticker: null
cik: "0001621227"
company_name: "Adaptimmune Therapeutics PLC"
filed_at: "2024-11-13T23:59:59+00:00"
generated_at: "2026-05-30T00:56:58.496808+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Adaptimmune reports Q3 net loss $17.6M; plans 33% headcount cut, $300M in savings through 2028

## Summary
- Q3 net loss $17.6M (EPS -$0.01); revenue $40.9M up from $7.3M due to Genentech/Astellas termination revenue.
- Plans 33% headcount reduction in Q1 2025; expects $300M cost savings over 4 years, targeting breakeven in 2027.
- Tecelra launch: 9 ATCs active, first patient apheresed; commercial revenues expected in Q4.
- Lete-cel pivotal trial: 42% ORR (6 CR, 21 PR) in synovial sarcoma/MRCLS; BLA planned by end-2025.
- Ended Q3 with total liquidity $186.1M; ceasing SURPASS-3 trial for ovarian cancer.

## SEC filing metadata
- accession: 0001558370-24-015525
- form_type: 8-K
- cik: 0001621227
- company_name: Adaptimmune Therapeutics PLC
- filed_at: 2024-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 2.05, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1621227/000155837024015525/0001558370-24-015525-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1621227/000155837024015525/adap-20241113x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-015525
- JSON: https://secwatch.observer/filing/0001558370-24-015525.json
- Plain text: https://secwatch.observer/filing/0001558370-24-015525.txt

## Key facts
- Restructurings & Charges
  Adaptimmune Therapeutics PLC announced a restructuring with charges of pre-tax costs of such reduction in workforce relating to employee severance and other employee-related costs may be in the region of $9-11 million affecting workforce reduction of approximately 33% (33% reduction in workforce).
  - Type: restructuring
  - Charge: pre-tax costs of such reduction in workforce relating to employee severance and other employee-related costs may be in the region of $9-11 million
  - Affected area: workforce reduction of approximately 33%
  - Headcount: 33% reduction in workforce
  source text: of 2025. The Company estimates that the pre-tax costs of such reduction in workforce relating to employee severance and other employee-related costs may be in the region of $9-11 million with the majority of such costs being incurred in the first quarter of 2025. The Company will provide further updates as it progresses through the restructuring
  evidence_url: https://www.sec.gov/Archives/edgar/data/1621227/000155837024015525/0001558370-24-015525-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.